Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Leishmaniasis (Kala-Azar)-Pipeline Review, H1 2015

Leishmaniasis (Kala-Azar)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Leishmaniasis (Kala-Azar)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Leishmaniasis (Kala-Azar)-Pipeline Review, H1 2015', provides an overview of the Leishmaniasis (Kala-Azar)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Leishmaniasis (Kala-Azar) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Leishmaniasis (Kala-Azar) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Leishmaniasis (Kala-Azar) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Leishmaniasis (Kala-Azar)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Leishmaniasis (Kala-Azar) Overview 10

Therapeutics Development 11

Pipeline Products for Leishmaniasis (Kala-Azar)-Overview 11

Pipeline Products for Leishmaniasis (Kala-Azar)-Comparative Analysis 12

Leishmaniasis (Kala-Azar)-Therapeutics under Development by Companies 13

Leishmaniasis (Kala-Azar)-Therapeutics under Investigation by Universities/Institutes 14

Leishmaniasis (Kala-Azar)-Pipeline Products Glance 15

Clinical Stage Products 15

Early Stage Products 16

Leishmaniasis (Kala-Azar)-Products under Development by Companies 17

Leishmaniasis (Kala-Azar)-Products under Investigation by Universities/Institutes 19

Leishmaniasis (Kala-Azar)-Companies Involved in Therapeutics Development 20

Advinus Therapeutics Ltd. 20

Anacor Pharmaceuticals, Inc. 21

Dafra Pharma International Ltd. 22

Georgia Tech Research Corporation 23

iCo Therapeutics Inc. 24

Merck KGaA 25

Mologen AG 26

Nanomerics Ltd 27

Sanofi 28

Takeda Pharmaceutical Company Limited 29

Zydus Cadila Healthcare Limited 30

Leishmaniasis (Kala-Azar)-Therapeutics Assessment 31

Assessment by Monotherapy Products 31

Assessment by Target 32

Assessment by Mechanism of Action 34

Assessment by Route of Administration 36

Assessment by Molecule Type 38

Drug Profiles 40

amphotericin b-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

amphotericin B-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

amphotericin b NanoDisk-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

AS-605240-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

CDRI-99/288-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

corifungin-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Drug to Inhibit PDE for Leishmaniasis and Trypanosomiasis-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Drugs for Leishmaniasis and Trypanosomiasis-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

fexinidazole-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Indotecan hydrochloride-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

KVH-14-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

leishmaniasis vaccine-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

leishmaniasis vaccine-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

leishmaniasis vaccine-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Methoxycoronaridine-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

MGN-1331-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

NPC-1161B-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Oleylphosphocholine-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

pegylated amphotericin B-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

S-010269-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Small Molecule for Leishmaniasis-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Small Molecule for Leishmaniasis-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Small Molecule for Visceral Leishmaniasis-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Small Molecules for Infectious Disease and Oncology-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Small Molecules for Infectious Diseases-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Small Molecules for Infectious Diseases-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

Small Molecules for Leishmaniasis-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Small Molecules for Leishmaniasis-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Small Molecules for Protozoal Infections-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

Small Molecules for Visceral Leishmaniasis-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

Small Molecules to Block LHR1 for Leishmaniasis-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

VGP-106-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

visceral leishmaniasis vaccine-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

VL-2098-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Leishmaniasis (Kala-Azar)-Recent Pipeline Updates 82

Leishmaniasis (Kala-Azar)-Dormant Projects 84

Leishmaniasis (Kala-Azar)-Discontinued Products 85

Leishmaniasis (Kala-Azar)-Product Development Milestones 86

Featured News & Press Releases 86

Feb 13, 2015: Nanomerics Oral Amphotericin B Promises Better Treatment for Millions 86

Nov 03, 2014: Presentation of DNA vaccine against leishmaniasis at IMED 2014 86

Oct 06, 2014: Phase III Clinical Study in Ethiopia Launched to Test Two Treatments for HIV-Visceral Leishmaniasis Co-infected Patients 86

Mar 19, 2014: Knight Therapeutics Announces FDA Approval for Impavido (Miltefosine) for the Treatment of Visceral, Mucosal and Cutaneous Leishmaniasis 88

Nov 11, 2013: Paladin Announces Extension of the Impavido PDUFA Date by Three Months 88

Jun 19, 2013: Paladin Receives Priority Review Status From FDA For Impavido NDA Submission For Treatment Of Leishmaniasis 88

Dec 17, 2012: PATH's Drug Development Program Announces Successful Completion Of Phase IIIb Clinical Trial Of Paromomycin Intramuscular Injection In Bangladesh 89

Jun 26, 2012: Leishdnavax Consortium Successfully Concludes Preclinical Development Of MGN1331 DNA Vaccine Against Leishmaniasis 89

Mar 06, 2012: 10 million boost for neglected tropical disease research at Dundee 90

Feb 22, 2012: IDRI Launches First Clinical Trial For New Vaccine To Treat Leishmaniasis 91

Appendix 93

Methodology 93

Coverage 93

Secondary Research 93

Primary Research 93

Expert Panel Validation 93

Contact Us 93

Disclaimer 94

List of Tables

Number of Products under Development for Leishmaniasis (Kala-Azar), H1 2015 11

Number of Products under Development for Leishmaniasis (Kala-Azar)-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Products under Development by Companies, H1 2015 (Contd..1) 18

Products under Investigation by Universities/Institutes, H1 2015 19

Leishmaniasis (Kala-Azar)-Pipeline by Advinus Therapeutics Ltd., H1 2015 20

Leishmaniasis (Kala-Azar)-Pipeline by Anacor Pharmaceuticals, Inc., H1 2015 21

Leishmaniasis (Kala-Azar)-Pipeline by Dafra Pharma International Ltd., H1 2015 22

Leishmaniasis (Kala-Azar)-Pipeline by Georgia Tech Research Corporation, H1 2015 23

Leishmaniasis (Kala-Azar)-Pipeline by iCo Therapeutics Inc., H1 2015 24

Leishmaniasis (Kala-Azar)-Pipeline by Merck KGaA, H1 2015 25

Leishmaniasis (Kala-Azar)-Pipeline by Mologen AG, H1 2015 26

Leishmaniasis (Kala-Azar)-Pipeline by Nanomerics Ltd, H1 2015 27

Leishmaniasis (Kala-Azar)-Pipeline by Sanofi, H1 2015 28

Leishmaniasis (Kala-Azar)-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 29

Leishmaniasis (Kala-Azar)-Pipeline by Zydus Cadila Healthcare Limited, H1 2015 30

Assessment by Monotherapy Products, H1 2015 31

Number of Products by Stage and Target, H1 2015 33

Number of Products by Stage and Mechanism of Action, H1 2015 35

Number of Products by Stage and Route of Administration, H1 2015 37

Number of Products by Stage and Molecule Type, H1 2015 39

Leishmaniasis (Kala-Azar) Therapeutics-Recent Pipeline Updates, H1 2015 82

Leishmaniasis (Kala-Azar)-Dormant Projects, H1 2015 84

Leishmaniasis (Kala-Azar)-Discontinued Products, H1 2015 85

List of Figures

Number of Products under Development for Leishmaniasis (Kala-Azar), H1 2015 11

Number of Products under Development for Leishmaniasis (Kala-Azar)-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Products, H1 2015 16

Assessment by Monotherapy Products, H1 2015 31

Number of Products by Top 10 Targets, H1 2015 32

Number of Products by Stage and Top 10 Targets, H1 2015 33

Number of Products by Top 10 Mechanism of Actions, H1 2015 34

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 35

Number of Products by Top 10 Routes of Administration, H1 2015 36

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 37

Number of Products by Top 10 Molecule Types, H1 2015 38

Number of Products by Stage and Top 10 Molecule Types, H1 2015 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Advinus Therapeutics Ltd.

Anacor Pharmaceuticals, Inc.

Dafra Pharma International Ltd.

Georgia Tech Research Corporation

iCo Therapeutics Inc.

Merck KGaA

Mologen AG

Nanomerics Ltd

Sanofi

Takeda Pharmaceutical Company Limited

Zydus Cadila Healthcare Limited

Leishmaniasis (Kala-Azar) Therapeutic Products under Development, Key Players in Leishmaniasis (Kala-Azar) Therapeutics, Leishmaniasis (Kala-Azar) Pipeline Overview, Leishmaniasis (Kala-Azar) Pipeline, Leishmaniasis (Kala-Azar) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com